U.S. Pharma Stock News

MKS Inc. has already reported its first-quarter 2026 results, with revenue rising to US$1,078 million from US$936 million a year earlier and net income increasing to US$84 million from US$52 million, lifting basic earnings per share from continuing operations to US$1.24. The quarter also capped months of higher analyst expectations and came after a February refinancing that pushed debt maturities into the 2030s and cut annual cash interest by about US$27 million, improving MKS's financial...

FIGS (FIGS) closed out FY 2025 with Q4 revenue of US$201.9 million and basic EPS of US$0.11, alongside trailing 12 month revenue of US$631.1 million and EPS of US$0.21 that has been described as posting a very large year on year gain. The company has seen quarterly revenue move from US$140.2 million in Q3 2024 to US$201.9 million in Q4 2025, while basic EPS shifted from a loss of US$0.01 in Q3 2024 to US$0.11 in the latest quarter. This has set up a story where forecast earnings growth of...

DXC Technology (DXC) just posted its Q3 2026 numbers with revenue of US$3.2 billion and basic EPS of US$0.62 on net income of US$107 million, setting a clear marker for how the turnaround is tracking. The company has seen quarterly revenue hold around the US$3.2 billion level over the past six periods, while basic EPS has moved from US$0.23 in Q2 2025 to US$0.62 in Q3 2026 as net income shifted from US$42 million to US$107 million over that span. For investors watching margins and earnings...

Definitive Healthcare (DH) has just closed out FY 2025 with Q4 revenue of US$61.5 million and a basic EPS loss of US$0.09, alongside trailing twelve month revenue of US$241.5 million and a TTM basic EPS loss of US$1.30. This gives investors a clear read on the current earnings profile. Over the past few quarters, revenue has ranged from US$59.2 million to US$62.7 million, while quarterly basic EPS losses have moved between US$0.07 and US$1.12. This sets the backdrop for a business that is...

Tandem Diabetes Care (TNDM) has wrapped up FY 2025 with Q4 revenue of US$290.4 million and a basic EPS loss of US$0.01, framing a year in which the trailing twelve months show US$1.0 billion of revenue and a basic EPS loss of US$3.04. Over recent quarters, revenue has moved from US$282.6 million in Q4 2024 to US$234.4 million in Q1 2025, then to US$240.7 million in Q2, US$249.3 million in Q3 and back to US$290.4 million in Q4 2025. Quarterly basic EPS has ranged from a small profit of US$0.01...

InfuSystem Holdings (INFU) closed out FY 2025 with fourth quarter revenue of US$36.2 million and basic EPS of US$0.10, as part of a trailing twelve month profile that shows revenue of US$143.4 million and EPS of about US$0.32. Over the past few reported periods, the company has seen quarterly revenue move from US$33.8 million and EPS of US$0.04 in Q4 2024 to US$36.2 million and EPS of US$0.10 in Q4 2025, with trailing twelve month EPS shifting from roughly US$0.11 to US$0.32 alongside higher...

Nomad Foods (NYSE:NOMD) has just posted its FY 2025 numbers, with fourth quarter revenue of €773.1 million and a basic EPS loss of €0.07, while trailing 12 month net income came in at €136.7 million on €3.0 billion of revenue and a 4.5% net margin that was below the prior year's 7.3%. Over recent quarters, revenue has moved from €793.4 million and EPS of €0.32 in Q4 2024 to a range between €746.9 million and €773.1 million in FY 2025. Quarterly EPS has swung between €0.21 and €0.44 before...

Akamai Technologies (AKAM) FY 2025 earnings snapshot Akamai Technologies (AKAM) has wrapped up FY 2025 with fourth quarter revenue of US$1,094.9 million and basic EPS of US$0.59, set against trailing twelve month revenue of US$4.2 billion and EPS of US$3.11 that frame the latest print within a fuller year view. Over recent periods the company has seen quarterly revenue move from US$1,019.9 million and EPS of US$0.93 in Q4 2024 through US$1,015.1 million and EPS of US$0.83 in Q1 2025 to...

Willdan Group (WLDN) closed out FY 2025 with Q4 revenue of US$173.7 million and basic EPS of US$1.28, supported by trailing twelve month revenue of US$681.6 million and EPS of US$3.63. Over the past few quarters, revenue has ranged from US$152.4 million in Q1 2025 to US$182.0 million in Q3 2025. Quarterly EPS has moved from US$0.33 to US$1.28, with trailing net profit margin at 7.7% compared with 4% a year earlier and reported earnings growth of 131.8% over that period. For investors, that...

Hormel Foods (NYSE:HRL) has partnered with OluKai to release a limited-edition SPAM inspired sandal collection, tying into the brand's strong identity in Hawai'i and abroad. The company has also signed a new licensing agreement with Disguise, Inc. to create costumes based on several Hormel brands. These moves extend Hormel's reach beyond grocery aisles into lifestyle and entertainment products. At a share price of $20.75, Hormel Foods sits against a backdrop of weak recent stock...

Puma Biotechnology (PBYI) closed FY 2025 with Q4 revenue of US$75.5 million and basic EPS of US$0.27, alongside net income of US$13.4 million that helped deliver trailing twelve month net income of US$31.1 million and basic EPS of US$0.62. Over recent quarters, the company has seen revenue move from US$46.0 million and EPS of US$0.06 in Q1 2025 to US$75.5 million and EPS of US$0.27 in Q4 2025. This positions investors to focus on how steadily improving margins underpin the current earnings...

Zymeworks (ZYME) closed out FY 2025 with Q4 revenue of US$2.5 million and a basic EPS loss of US$0.55, while net income excluding extra items was a loss of US$41.2 million, setting a cautious tone around margins and scale. Over the past four quarters, the company has seen total revenue range from US$2.5 million to US$48.7 million per quarter and basic EPS swing between a small profit of US$0.03 and a loss of US$0.55. This gives investors a wide earnings range to weigh against forecasts and...

Cytek Biosciences (CTKB) closed out FY 2025 with Q4 revenue of US$62.1 million and a basic EPS loss of US$0.34, alongside a trailing twelve month revenue base of US$201.5 million and a basic EPS loss of US$0.52. Over recent periods, the company has seen quarterly revenue move from US$57.5 million in Q4 2024 to US$62.1 million in Q4 2025, while basic EPS shifted from a profit of US$0.07 in Q4 2024 to a loss of US$0.34 in Q4 2025. This sets up a story that puts margin pressure and the path back...

In April 2026, HCA Healthcare held its annual shareholder meeting, reported voting results that rejected two shareholder proposals, announced a leadership change in marketing and corporate affairs, and filed an omnibus shelf registration for common stock, preferred stock, and debt securities. These governance, leadership, and financing developments come alongside HCA’s continued emphasis on nursing excellence and community partnerships, highlighting how corporate decisions intersect with...

Gen Digital Q3 2026 results in focus Gen Digital (GEN) has put fresh numbers on the table for Q3 2026, reporting revenue of US$1.2 billion and basic EPS of US$0.31 as investors weigh these results against a share price around US$20.19. Over recent quarters, the company has seen quarterly revenue move from US$986 million in Q3 2025 to US$1.2 billion in Q3 2026, while basic EPS has shifted from US$0.26 to US$0.31. This update comes against a backdrop of moderate top-line growth and margins that...

Why Valvoline (VVV) has drawn fresh attention Valvoline (VVV) is back on many watchlists after a recent move that left the stock up about 5% over the past week and roughly 24% year to date. For investors, that shift is prompting a closer look at how the company’s current $4.35b market value, recent revenue of $1,858.4m, and net income of $95.7m line up with its broader return profile. See our latest analysis for Valvoline. The recent 1 day share price return of 4.98% and 7 day share price...

Definium Therapeutics (DFTX) stock is in focus after the company reported first quarter 2026 results, including a net loss of US$77.1 million, compared with US$23.35 million in the same period a year earlier. See our latest analysis for Definium Therapeutics. The earnings update comes after a strong run in the stock, with a 90 day share price return of 37.28% and a year to date share price return of 70.09%. Meanwhile, the 1 year total shareholder return of 259.13% and 3 year total shareholder...

Turning Point Brands (TPB) opened 2026 with Q1 revenue of US$124.3 million and basic EPS of US$0.61, alongside net income from continuing operations of US$11.7 million, setting a clear reference point for how the year is starting to shape up. The company has seen quarterly revenue move from US$106.4 million in Q1 2025 to US$124.3 million in Q1 2026, while basic EPS over that span has ranged between US$0.43 and US$1.16, giving you a fuller view of how top line and per share earnings have...

OmniAb FY 2025 earnings snapshot OmniAb (NasdaqGM:OABI) has wrapped up FY 2025 with fourth quarter revenue of US$8.4 million, a basic EPS loss of US$0.11, and a net loss of US$14.2 million, putting hard numbers around a year where growth expectations and ongoing losses are both in focus. Over recent periods, the company has seen quarterly revenue range from US$2.2 million to US$10.8 million and basic EPS move between a loss of US$0.11 and a loss of US$0.17. This gives investors a clear view...

Sterling Infrastructure (STRL) is back in focus after an unusually strong first quarter, with revenue and earnings well ahead of Wall Street expectations and full year 2026 guidance lifted considerably. See our latest analysis for Sterling Infrastructure. The recent rally around Sterling Infrastructure has been sharp, with a 7 day share price return of 57.37% and a 30 day share price return of 112.29% following its Q1 earnings beat, raised 2026 guidance and ongoing acquisition push. At the...

Interface (TILE) just closed out FY 2025 with Q4 revenue of US$349.4 million and basic EPS of US$0.42, alongside trailing twelve month revenue of US$1.39b and EPS of US$1.99 that frame the full year picture. Over the past six quarters, revenue has moved from US$335.0 million in Q4 FY 2024 to US$349.4 million in Q4 FY 2025, while quarterly EPS shifted from US$0.37 to US$0.42 and trailing net profit margins improved from 6.6% to 8.4%, giving investors a clearer read on how earnings power is...

Progyny (PGNY) has wrapped up FY 2025 with fourth quarter revenue of US$318.4 million and basic EPS of US$0.15, while trailing 12 month figures show revenue of about US$1.3 billion and EPS of US$0.68 alongside 7.7% earnings growth over the past year. Over recent periods the company has seen quarterly revenue move from US$298.4 million in Q4 2024 to US$318.4 million in Q4 2025, with basic EPS shifting from US$0.12 to US$0.15, and trailing 12 month earnings rising from US$54.3 million to...

In late April 2026, Landstar System, Inc. reported first-quarter sales of US$1,149.56 million and net income of US$39.44 million, lifted earnings per share to US$1.16, completed a long-running share repurchase program totaling 15,202,552 shares for US$1.53 billions, and affirmed a quarterly dividend of US$0.40 per share. Together, the stronger quarterly earnings, meaningful reduction in share count over time, and continued cash returns through dividends highlight management’s focus on...

Intuit (INTU) has drawn fresh investor attention after launching QuickBooks Workforce, an AI powered human capital management platform that pulls payroll, HR, recruiting, benefits, and compliance into a single integrated system. See our latest analysis for Intuit. The QuickBooks Workforce launch comes after a tougher stretch for investors, with a 90 day share price return of an 8.34% decline and a 1 year total shareholder return of a 37.49% loss. However, recent 1 day and 7 day share price...